Now Covered by Most Payers

Mitigare® and/or Generic Colchicine Capsules are covered by more than 80% of plans*

Due to recent formulary changes, patients covered by Medicare, Medicaid and many major commercial insurance plans should have more access and coverage for their Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine Capsules prescriptions.

Click on our announcements below to find out more about each coverage update.

*Managed Markets Insight & Technology, LLC database and formulary status as of May 1, 2019.

Recent Announcements

Other Updates

Effective October 1, 2019
Mitigare® (colchicine) 0.6mg Capsules are the Only Preferred Brand on the Alabama Medicaid Preferred Drug List (PDL).*
Details: *Generic Colchicine Capsules are also preferred on the Alabama PDL. All other products in this category are either non-preferred or require prior authorization on the Alabama PDL.

Effective July 1, 2019
Mitigare® (colchicine) 0.6mg Capsules are now Preferred on the South Carolina Medicaid Preferred Drug List (PDL).*
Details: *Colcrys® (colchicine, USP) tablets, colchicine tablets and colchicine capsules require prior authorization on South Carolina Medicaid Preferred Drug List (PDL)

Effective May 1, 2019
Colchicine Capsules are now Preferred on the Louisiana Medicaid Preferred Drug List

Effective April 1, 2019
Mitigare® and Authorized Generic Colchicine Capsules are now Preferred on the Blue Cross Blue Shield (BCBS) Illinois Community Health Plans*
Details: *Colcrys® (colchicine, USP) tablets and colchicine tablets require prior authorization on BCBS Illinois Community Health Plans formulary.

Effective Jan 1, 2019
Mitigare® is now Available on Medi-Cal’s Contract Drug List

*Colcrys® is a registered trademark of Takeda Pharmaceuticals America, Inc.

Inventory Alert

Don’t forget to replenish your inventory of Mitigare® and Authorized Generic Colchicine Capsules. Visit our Pharmacist Information page to learn more about Mitigare® and our co-pay savings program, True Blue Savings.

 

Mitigare (Colchicine) 0.6 mg Capsules

ProductNDC#Bottle
Mitigare® 0.6 mg Capsules59467-318-3030 ct
Mitigare® 0.6 mg Capsules59467-318-01100 ct
Mitigare® 0.6 mg Capsules59467-318-101,000 ct

Authorized Generic Colchicine 0.6 mg Capsules

ProductNDC#Bottle
Colchicine 0.6 mg Capsules0143-3018-3030 ct
Colchicine 0.6 mg Capsules0143-3018-01100 ct
Colchicine 0.6 mg Capsules0143-3018-101,000 ct

Mitigare® Pharmacy Sell Sheet

Take a closer look at dispensing information for Mitigare® Colchicine Capsules and Authorized Generic Colchicine Capsules.

DOWNLOAD

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Read More...

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.